Introduction
Improvement of long-term outcomes in multiple myeloma critically relies on a better understanding of the tumor-initiating cell in this disease. As in other malignancies the cancer stem cell concept incriminates drug-resistant myeloma stem cells with tumorinitiating, self-renewing properties to feed the M-PC compartment in disease relapse and progression. 1, 2 However, it remains a matter of controversy if the clonogenic population resides within the pool of terminally differentiated post-switch M-PC or within a less differentiated (surface) immunoglobulin (Ig)-positive pre-switch B-cell compartment. The latter hypothesis has been fueled by the description of so-called clonotypic pre-switch (IgM+) B-cells postulated to express the same patient-individual variable region Ig rearrangement as the M-PC. [3] [4] [5] [6] [7] This finding even provided the rationale for therapeutic targeting of this postulated CD20+ population with the monoclonal antibody rituximab. 8, 9 However, inconsistent results of xenotransplantation experiments [10] [11] [12] [13] [14] [15] , data on intraclonal evolution at the PC level [16] [17] [18] [19] [20] [21] [22] , the analysis of class switch junctions 23 , and the lack of benefit from CD20-directed targeted therapy 8, 9 challenged the concept of such feeder cells in myeloma.
Moreover, a recent study entirely failed to detect clonotypic rearrangements in highly purified B-cell populations devoid of contaminating M-PC 24 , and our own data also pointed in this direction, since we could not phenotypically detect clonotypic B-cells in the majority of patients with patient-individual Ig ligands as tracers.
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Here we used next-generation sequencing to definitively confirm or disprove the existence of this highly controversial cell population. Figure 1A , B, D and Supplementary Table 2 .
NGS of Ig repertoires. Ig transcripts were amplified for NGS from peripheral blood as described in the Supplementary Detailed Methods Section. The amplification strategy and primer sequences are shown in Supplementary Figure 1C and Supplementary 
Results and Discussion

PCR-based detection of clonotypic peripheral blood cells
Peripheral blood clonotypic rearrangements were qualitatively detectable with HCDR3-specific primers in 6/8 patients with active disease, suggesting the presence of circulating clonotypic B-lineage cells (data not shown). None of the cases in remission after treatment was PCR-positive. All HCDR3 PCR-positive cases were also positive in an established semi-nested PCR approach using IgM-specific This finding suggested ongoing sequential switch events in the progeny of postswitch myeloma cells and therefore clonal evolution at the PC level.
Flow cytometry-based detection of circulating PCs
To confirm our assumption that the clonotypic post-switch rearrangements may 
Discussion of data in the context of previously published work
The hypothesis that pre-switch clonotypic B-cells act as tumor-initiating andpropagating cells in myeloma has caused considerable debate over decades. The results presented here should terminate this controversy. Using highly sensitive and highly specific state-of-the-art technology, we disprove the existence of such cells in the blood. This is in accordance with a recently growing body of evidence by other studies. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Two methodological aspects most likely account for the discrepancy between prior reports 3-7 and our study. First, PCR with HCDR3-and isotype-specific primers may lack specificity in the presence of abundant clonotypic transcripts of alternative For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
